Sponsor or institution
Clinical trials and research at Taxis Pharmaceuticals, INC.
As of November 12, 2026, Find a Trial lists 5 NIH-funded research projects at this institution, with $4.1 million in listed awards. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5NIH research projects
NIH-funded research (5)
Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.
-
Oral DHFR inhibitor to fight drug-resistant gonorrhea
A small, fast-moving funding program aims to develop an oral antibiotic that targets drug-resistant Neisseria gonorrhoeae and could help people who currently have few treatment options.
-
Oral FtsZ inhibitors to treat C. difficile infections
A small business research project tests a new oral drug class designed to treat C. difficile infections by targeting a key bacterial protein, with studies focused on gut-localized action in early development.
-
Lead-optimization of a new antibiotic helper to fight Pseudomonas infections
A new compound is being developed to boost the effectiveness of levofloxacin against drug-resistant Pseudomonas infections in hospitals.
-
Developing a new oral antibiotic to treat drug-resistant gonorrhea infections.
This study is working on a new pill to help treat gonorrhea, especially the tough strains that don't respond to current medicines, so patients can have a better and safer option for getting better.
-
Improving treatment for pneumonia caused by drug-resistant bacteria
This study is testing a new treatment that combines a special compound with an antibiotic to help fight tough infections like hospital-acquired pneumonia and ventilator-associated pneumonia caused by resistant bacteria, and it could help patients get better faster.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.